Tumor necrosis factor α decreases nitric oxide synthase type 3 expression primarily via rho/rho kinase in the thick ascending limb

Hypertension

Volumn 59, Issue 6, 2012, Pages 1145-1150

  Ramseyer, Vanesa D ^a,b   Hong, Nancy J ^a   Garvin, Jeffrey L ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; eNOS; Hypertension; Kidney

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN LIGHT CHAIN KINASE; NITRIC OXIDE; PROTEIN KINASE C; RAC1 PROTEIN; RHO FACTOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; LIMB; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; THICK ASCENDING LIMB; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; LOOP OF HENLE; MALE; MICROSCOPY, FLUORESCENCE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PRIMARY CELL CULTURE; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861517212     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.189761     Document Type: Article

References (49)

1. Greger R. Ion transport mechanisms in thick ascending limb of Henle's loop of mammalian nephron. Physiol Rev. 1985;65:760-797.
2. Hoagland KM, Flasch AK, Dahly-Vernon AJ, dos Santos EA, Knepper MA, Roman RJ. Elevated BSC-1 and ROMK expression in Dahl saltsensitive rat kidneys. Hypertension. 2004;43:860-865.
3. Garcia NH, Plato CF, Stoos BA, Garvin JL. Nitric oxide-induced inhibition of transport by thick ascending limbs from Dahl salt-sensitive rats. Hypertension. 1999;34:508-513.
4. Plato CF, Shesely EG, Garvin JL. eNOS mediates L-arginine-induced inhibition of thick ascending limb chloride flux. Hypertension. 2000;35: 319-323.
5. Ortiz PA, Hong NJ, Garvin JL. Luminal flow induces eNOS activation and translocation in the rat thick ascending limb. II. Role of PI3-kinase and Hsp90. Am J Physiol Renal Physiol. 2004;287:F281-F288.
6. Herrera M, Garvin JL. Endothelin stimulates endothelial nitric oxide synthase expression in the thick ascending limb. Am J Physiol Renal Physiol. 2004;287:F231-F235.
7. Herrera M, Garvin JL. Angiotensin II stimulates thick ascending limb NO production via AT(2) receptors and Akt1-dependent nitric-oxide synthase 3 (NOS3) activation. J Biol Chem. 2010;285:14932-14940.
8. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1-R12.
9. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998;97:2494-2498.
10. Herrera M, Hong NJ, Ortiz PA, Garvin JL. Endothelin-1 inhibits thick ascending limb transport via Akt-stimulated nitric oxide production. J Biol Chem. 2009;284:1454-1460.
11. Herrera M, Silva GB, Garvin JL. A high-salt diet dissociates NO synthase-3 expression and NO production by the thick ascending limb. Hypertension. 2006;47:95-101.
12. Perez-Rojas JM, Kassem KM, Beierwaltes WH, Garvin JL, Herrera M. Nitric oxide produced by endothelial nitric oxide synthase promotes diuresis. Am J Physiol Regul Integr Comp Physiol. 2010;298: R1050-R1055.
13. Alexander BT, Cockrell KL, Massey MB, Bennett WA, Granger JP. Tumor necrosis factor-β-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am J Hypertens. 2002;15:170-175.
14. Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A. Association of cardiovascular risk factors and endothelial dysfunction in japanese hypertensive patients: implications for early atherosclerosis. Hypertens Res. 2002;25:475-480.
15. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens. 2005;19:149-154.
16. Agnoletti L, Curello S, Bachetti T, Malacarne F, Gaia G, Comini L, Volterrani M, Bonetti P, Parrinello G, Cadei M, Grigolato PG, Ferrari R. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-α. Circulation. 1999;100: 1983-1991.
17. Ferreri NR, Escalante BA, Zhao Y, An SJ, McGiff JC. Angiotensin II induces TNF production by the thick ascending limb: functional implications. Am J Physiol. 1998;274:F148-F155.
18. Elmarakby AA, Quigley JE, Pollock DM, Imig JD. Tumor necrosis factoRblockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension. 2006;47: 557-562.
19. Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis factor-αin angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008;51:1345-1351.
20. Tran LT, MacLeod KM, McNeill JH. Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats. Mol Cell Biochem. 2009;330:219-228.
21. Venegas-Pont M, Manigrasso MB, Grifoni SC, LaMarca BB, Maric C, Racusen LC, Glover PH, Jones AV, Drummond HA, Ryan MJ. Tumor necrosis factor-αantagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension. 2010;56:643-649.
22. Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, Pisconti A, Palomba L, Cantoni O, Clementi E, Moncada S, Carruba MO, Nisoli E. TNF-α downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest. 2006;116:2791-2798.
23. Alonso J, Sanchez dM, Monton M, Casado S, Lopez-Farre A. Endothelial cytosolic proteins bind to the 3= untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factoR. Mol Cell Biol. 1997;17:5719-5726.
24. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73:205-209.
25. Bao HF, Zhang ZR, Liang YY, Ma JJ, Eaton DC, Ma HP. Ceramide mediates inhibition of the renal epithelial sodium channel by tumor necrosis factor-αthrough protein kinase C. Am J Physiol Renal Physiol. 2007;293:F1178-F1186.
26. Wu X, Guo R, Chen P, Wang Q, Cunningham PN. TNF induces caspasedependent inflammation in renal endothelial cells through a Rho-and myosin light chain kinase-dependent mechanism. Am J Physiol Renal Physiol. 2009;297:F316-F326.
27. Kakiashvili E, Speight P, Waheed F, Seth R, Lodyga M, Tanimura S, Kohno M, Rotstein OD, Kapus A, Szaszi K. GEF-H1 mediates tumor necrosis factor-β-induced Rho activation and myosin phosphorylation: role in the regulation of tubular paracellular permeability. J Biol Chem. 2009;284:11454-11466.
28. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNf-induced apoptosis. Cell. 2003;115:61-70.
29. Papaharalambus C, Sajjad W, Syed A, Zhang C, Bergo MO, Alexander RW, Ahmad M. Tumor necrosis factoRstimulation of Rac1 activity: role of isoprenylcysteine carboxylmethyltransferase. J Biol Chem. 2005;280: 18790-18796.
30. Barsacchi R, Perrotta C, Bulotta S, Moncada S, Borgese N, Clementi E. Activation of endothelial nitric-oxide synthase by tumor necrosis factor-α: a novel pathway involving sequential activation of neutral sphingomyelinase, phosphatidylinositol-3= kinase, and Akt. Mol Pharmacol. 2003;63:886-895.
31. Ramseyer V, Garvin JL. Angiotensin II decreases NOS3 expression via nitric oxide and superoxide in the thick ascending limb. Hypertension. 2008;53:313-318.
32. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273: 24266-24271.
33. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002;106:57-62.
34. Eto M, Barandier C, Rathgeb L, Kozai T, Joch H, Yang Z, Luscher TF. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res. 2001;89: 583-590.
35. El-Remessy AB, Tawfik HE, Matragoon S, Pillai B, Caldwell RB, Caldwell RW. Peroxynitrite mediates diabetes-induced endothelial dysfunction: possible role of Rho kinase activation. Exp Diabetes Res. 2010;2010:247861.
36. Cabral PD, Hong NJ, Garvin JL. Shear stress increases nitric oxide production in thick ascending limbs. Am J Physiol Renal Physiol. 2010; 299:F1185-F1192.
37. Yosef Hochberg. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-802.
38. Peng J, He F, Zhang C, Deng X, Yin F. Protein kinase C-αsignals P115RhoGEF phosphorylation and RhoA activation in TNF-β-induced mouse brain microvascular endothelial cell barrier dysfunction. J Neuroinflammation. 2011;8:28.
39. Shin SJ, Lai FJ, Wen JD, Lin SR, Hsieh MC, Hsiao PJ, Tsai JH. Increased nitric oxide synthase mRNA expression in the renal medulla of waterdeprived rats. Kidney Int. 1999;56:2191-2202.
40. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357:593-615.
41. Xia Z, Liu M, Wu Y, Sharma V, Luo T, Ouyang J, McNeill JH. N-acetylcysteine attenuates TNF-β-induced human vascular endothelial cell apoptosis and restores eNOS expression. Eur J Pharmacol. 2006; 550:134-142.
42. Goodwin BL, Pendleton LC, Levy MM, Solomonson LP, Eichler DC. Tumor necrosis factor-αreduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. Am J Physiol Heart Circ Physiol. 2007;293:H1115-H1121.
43. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(α)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther. 2002;93:225-232.
44. Yang B, Rizzo V. TNF-αpotentiates protein-tyrosine nitration through activation of NADPH oxidase and eNOS localized in membrane rafts and caveolae of bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol. 2007;292:H954-H962.
45. Mohamed F, Monge JC, Gordon A, Cernacek P, Blais D, Stewart DJ. Lack of role for nitric oxide (NO) in the selective destabilization of endothelial NO synthase mRNA by tumor necrosis factor-α. Arterioscler Thrombo Vasc Biol. 1995;15:52-57.
46. Anderson HD, Rahmutula D, Gardner DG. Tumor necrosis factor- αinhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem. 2004;279:963-969.
47. Ramana KV, Tammali R, Reddy AB, Bhatnagar A, Srivastava SK. Aldose reductase-regulated tumor necrosis factor-αproduction is essential for high glucose-induced vascular smooth muscle cell growth. Endocrinology. 2007;148:4371-4384.
48. Coughlan MT, Oliva K, Georgiou HM, Permezel JM, Rice GE. Glucoseinduced release of tumour necrosis factor-αfrom human placental and adipose tissues in gestational diabetes mellitus. Diabet Med. 2001;18: 921-927.
49. Rothe H, Ongoren C, Martin S, Rosen P, Kolb H. Abnormal TNF-αproduction in diabetes-prone BB rats: enhanced TNF-αexpression and defective PGE2 feedback inhibition. Immunology. 1994;81:407-413.